Ocular Therapeutix (OCUL) Other Accumulated Expenses (2013 - 2026)

Ocular Therapeutix's Other Accumulated Expenses history runs 14 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 4.19% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 4.19% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, down 6.76% from the prior year.
• Other Accumulated Expenses slipped to $1.7 million in Q1 2026 per OCUL's latest filing, from $1.9 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.1 million in Q4 2024 and bottomed at $1.1 million in Q2 2022.
• The 5-year median for Other Accumulated Expenses is $1.6 million (2024), against an average of $1.6 million.
• Across the five-year window, Other Accumulated Expenses surged 61.58% in 2024 and dropped 10.53% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $1.2 million in 2022, then grew by 24.19% to $1.5 million in 2023, then soared by 34.75% to $2.1 million in 2024, then decreased by 6.76% to $1.9 million in 2025, then decreased by 13.0% to $1.7 million in 2026.
• Per Business Quant, the three latest OCUL Other Accumulated Expenses figures stand at $1.7 million (Q1 2026), $1.9 million (Q4 2025), and $1.9 million (Q3 2025).